retatrutide phase 2 nejm 2023 obesity trial jastreboff 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide, a TRIPLE agonist (GLP1,

Gasoyan added that, in this large observational study of patients who discontinued semaglutide or tirzepatide, reinitiation of the original medication or receipt of alternative obesity treatment was common, which may explain why they regained less weight than patients in randomized trials. Additionally, previous research suggests that GLP-1 drug discontinuation often occurs for practical reasons rather than lack of effectiveness

it includes the financial exploitation of individuals seeking genuine help for a serious health condition like obesity

Heres an overview of what to expect

Supplementary information Source data Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made

Tackling emotional triggers, stress, and mood can enhance long-term results